Directing chemotherapy to ctDNA-positive patients reduces overall chemotherapy use
A study showed that circulating tumour DNA (ctDNA) - genetic material shed from tumours into the bloodstream - can identify stage II colon cancer patients who can most benefit from chemotherapy following surgery and spare other patients the need for this form of treatment.